Noncirrhotic portal hypertension due to peripheral T-cell lymphoma, not otherwise specified: A case report

Miao-Miao Wu, Wen-Jun Fu, Jia Wu, Lin-Lin Zhu, Ting Niu, Rong Yang, Jin Yao, Qiang Lu, Xiao-Yang Liao

Abstract

BACKGROUND
Peripheral T-cell lymphoma (PTCL), an aggressive and rare disease that belongs to a heterogeneous group of mature T-cell lymphomas, develops rapidly and has a poor prognosis. Early detection and treatment are essential to improve patient cure and survival rates. Here, we report a rare case of PTCL with clinical presentation of noncirrhotic portal hypertension, which provides a basis for early vigilance of lymphomas in the future.

CASE SUMMARY
A 65-year-old Chinese woman was admitted to our hospital because of abdominal distension for 3 months and pitting oedema of both lower limbs for 2 months. Physical examinations and associated auxiliary examinations showed the presence of hepatosplenomegaly, and her hepatic venous pressure gradient was 10 mmHg. Immunohistochemical analysis of the liver biopsy confirmed the diagnosis of PTCL. The patient underwent combination therapy with dexamethasone, VP-16, and chidamide. Unfortunately, after 41 days of chemotherapy, the patient died of multiple organ failure.

CONCLUSION
PTCL accompanied by noncirrhotic portal hypertension is rarely reported. This
case report discusses the diagnosis of a patient according to the literature.

**Key Words:** Noncirrhotic portal hypertension; Ascites; Peripheral T-cell lymphoma; Lymphoma; Chidamide; Case report

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Peripheral T-cell lymphoma (PTCL) is an aggressive and rare disease that belongs to a heterogeneous group of mature T-cell lymphomas, and is classified as PTCL, not otherwise specified (PTCL-NOS). It is the most common type and most often involves nodal sites; however, many patients present with extranodal involvement, including the liver, bone marrow, gastrointestinal tract, and skin. The clinical presentations of PTCL are lymphadenopathy syndrome and B symptoms (night sweats, fever, and weight loss). Noncirrhotic portal hypertension, hydrothorax, and ascites can also occur in rare cases, and noncirrhotic portal hypertension and ascites are less common as first symptoms. Here, we report a rare case of a patient with PTCL who presented with noncirrhotic portal hypertension.

**INTRODUCTION**

Peripheral T-cell lymphoma (PTCL) is an aggressive and rare disease that belongs to a heterogeneous group of mature T-cell lymphomas, and is classified as PTCL not otherwise specified (PTCL-NOS). It is the most common type and most often involves nodal sites; however, many patients present with extranodal involvement, including the liver, bone marrow, gastrointestinal tract, and skin[1]. The clinical presentations of PTCL are lymphadenopathy syndrome and B symptoms (night sweats, fever, and weight loss). Noncirrhotic portal hypertension, hydrothorax, and ascites can also occur in rare cases [2,3], and noncirrhotic portal hypertension and ascites are less common as first symptoms. Here, we report a rare case of a patient with PTCL who presented with noncirrhotic portal hypertension.

**CASE PRESENTATION**

**Chief complaints**

A 65-year-old Chinese woman was referred to our hospital due to abdominal distension for over 3 months and pitting oedema of both lower limbs for over 2 mo.

**History of present illness**

Approximately 3 mo previously, this patient was admitted to a local hospital due to abdominal distension. Additional symptoms included pitting oedema of both lower limbs, anorexia and melena, and the patient lost 5 kg in two months. The patient had no jaundice, fever, or night sweats. Ultrasonography (US) indicated that she had neither oesophageal nor gastric varices or ulcers. but gastroscopic examination showed external compression of large gastric curvature, the cause of gastric wall compression is unknown, taking into account the left side of lying stomach bend side close to the spleen. Extra-hospital computed tomography (CT) showed hepatosplenomegaly and no other lesions around the stomach. So we think the growth of the spleen is the most likely reason for the external pressure of the greater curvature of the stomach. After 10 days of albumin infusion therapy, the above symptoms were not relieved but rather further aggravated. Therefore, she was referred to a tertiary hospital.

**History of past illness**

She had no history of hepatitis and no significant past medical history.

**Physical examination**

The physical examination revealed that the patient had abdominal varices and an increase in abdominal circumference to 98 cm.
Laboratory examinations

Laboratory tests showed that her white blood cell count was $1.80\times10^9/L$ (reference value $3.5-9.5\times10^9/L$), the neutrophil count was $1.33\times10^9/L$ (reference value $1.8-6.3\times10^9/L$), the neutrophil percentage was $73.80\%$ (reference value $40%-75\%$), haemoglobin was $26.5\text{ g/L}$ (reference value $40.0-55.0\text{ g/L}$), platelet count was $54\times10^9/L$ (reference value $100-300\times10^9/L$), albumin was $25.3\text{ g/L}$, glucose was $6.85\text{ mmol/L}$, LDH was $347\text{ IU/L}$ (reference value $120-250\text{ IU/L}$), and liver and renal function were within normal limits. Her erythrocyte sedimentation rate was $3.0\text{ mm/h}$ (reference value $<38\text{ mm/h}$). Coagulation function revealed a prothrombin time of $18.2\text{ s}$ (reference value $9.6-12.8\text{ s}$), and fibrinogen was $0.64\text{ g/L}$ (reference value $2.0-4.0\text{ g/L}$) (Table 1). Tests for Epstein-Barr virus, tuberculosis, and hepatitis B, A, C, D, and E were all negative.

Imaging examinations

Positron emission tomography-CT (PET) indicated hepatosplenomegaly and swelling of the peritoneum, mesentery, descending duodenum, and horizontal segments (Figure 1). Liver ultrasound showed increased liver volume; no cirrhosis-specific nodular changes were observed, and liver stiffness was measured at $19.55\text{ kPa}$ (Figure 2). CT also showed an enlarged liver volume, parenchymal density, and acceptable strengthening, as well as a small, tiny cyst. Two sides of the intrahepatic portal vein showed no enhancement of the low-density strip, showing a "double-track sign". Consideration was given to the possibility of intrahepatic lymphatic stasis. Liver computed tomographic arteriography showed hepatosplenomegaly without portal vein, splenic vein, or mesenteric arteriovenous thrombosis (Figure 3).

FURTHER DIAGNOSTIC WORK-UP

Relevant laboratory data for ascites were as follows: appearance was yellow and cloudy, nucleated cells were $40\times10^6/L$, red blood cells were $6700\times10^6/L$, albumin was $25.3\text{ g/L}$, glucose was $6.85\text{ mmol/L}$, LDH was $246\text{ IU/L}$, serum-ascites LDH gradient was $0.87$, adenosine deaminase was $27.8\text{ IU/L}$, the serum-ascites albumin gradient (SAAG) was $1.3$, the ascitic fluid bacterial culture showed no bacterial growth, and the tuberculosis antibody test was negative. The hepatic venous pressure gradient (HVPG) measured by transjugular intrahepatic portosystemic shunt (TIPS) was $10\text{ mmHg}$. Ascites immunocytology showed that the lymphocyte population composition was approximately $93.3\%$ nucleated cells, of which approximately $14.5\%$ were weakly positive for CD5. Immunohistochemistry staining showed that the lymphocytes were positive for CD2, CD3, CD7, CD8, CD56, CD57, and T-cell receptor (TCR) $\alpha\beta$ but negative for CD11c, CD16, CD4, and TCR $\gamma\delta$. Because of the limitation of the medical technique used, DNA ploidy analysis of the exfoliated cells of the benign and malignant hydrothorax as well as flow cytometry of the ascites were not performed. Immunohistochemical analysis, performed on a bone marrow biopsy and aspiration (Figure 4), showed that cells were positive for CD3, CD7, and CD56 and negative for CD20, CD2, CD5, CD4, CD8, TIA-1, CD30, and CD34, as well as for Epstein–Barr virus-encoded RNAs, using in situ hybridization. Medical examination of ascites and bone marrow revealed a T-cell lymphoma. HVPG was measured by TIPS, liver biopsy was performed, and immunohistochemistry was performed. Macroscopically, 4 strips of grey yellow cord-like tissue, approximately $0.8-1.3\text{ cm}$ in length and $0.1\text{ cm}$ in diameter, were positive for CD3, CD5, CD7, CD8, CD43, CD56, TIA-1, and Ki-67 and negative for CD2, CD20, CD4, CD30, and CD34, and TdT (Figure 5). Gene rearrangements are seen in the TCR $\gamma$ low amplification peak (Table 2).

FINAL DIAGNOSIS

Eventually, after twenty days, the patient was diagnosed with an aggressive T-cell lymphoma (stage IV), which was categorised as a PTCL-NOS.

TREATMENT

The patient was diagnosed with T-cell lymphoma and was given $5\text{ mg}$ dexamethasone once a day. After four days of hormone therapy, the patient's oedema of both lower extremities was alleviated, but the reduction was not obvious; therefore, $25\text{ mg}$ etoposide once a week was added. After two days, the oedema of both lower limbs was significantly improved; however, ascitic changes were unremarkable. After 12 days, the patient was put on chidamide chemotherapy at the recommended starting dose of $20\text{ mg}$, 1 to 3 times per week, $20$ to $50\text{ mg}$ each time; the patient took the medication for 22 days with a cumulative dose of $110\text{ mg}$, and the oedema of both lower limbs disappeared completely; however, ascites remained unchanged.
Table 1: Main laboratory test results

| Laboratory tests       | Result         | Reference value          |
|------------------------|----------------|--------------------------|
| White blood cell count | $1.80 \times 10^9$/L | $3.5-9.5 \times 10^9$/L   |
| Neutrophil count       | $1.33 \times 10^9$/L | $1.8-6.3 \times 10^9$/L   |
| Neutrophil percentage  | 0.738          | 40-75%                   |
| Haemoglobin            | 71 g/L         | 115-150 g/L              |
| Platelet count         | $54 \times 10^9$/L | $100-300 \times 10^9$/L  |
| Albumin                | 26.5 g/L       | 40.0-55.0 g/L            |
| Lactate dehydrogenase  | 347 IU/L       | 120-250 IU/L             |
| Erythrocyte sedimentation rate | 3.0 mm/h | < 38 mm/h |
| Coagulation function revealed a prothrombin time of | 18.2 s | 9.6-12.8 s |
| Fibrinogen             | 0.64 g/L       | 2.0-4.0 g/L              |

Table 2: Immunohistochemistry of pleural fluid, ascites, liver, and bone marrow

| Parameter    | Marrow | Ascites | Hydrothorax | Liver |
|--------------|--------|---------|-------------|-------|
| CD2          | ++     | +       | +           | -     |
| CD3          | ++     | ++      | +           | +     |
| CD4          | -      | -       | -           | -     |
| CD5          | +      | +       | +           | +     |
| CD7          | ++     | ++      | ++          | +     |
| CD8          | +      | +       | ++          | +     |
| CD11c        | -      | -       | -           | -     |
| CD16         | -      | +       | -           | -     |
| CD30         | -      | -       | -           | -     |
| CD34         | -      | -       | -           | -     |
| CD38         | -      | -       | ++          | -     |
| CD43         | -      | -       | +           | -     |
| CD45         | +      | +       | +           | -     |
| CD56         | ++     | ++      | ++          | +     |
| CD57         | +      | +p      | ++          | +     |
| TCRαβ        | +      | +       | +           | +     |
| TCRγδ        | -      | -       | -           | -     |
| TIA-1        | -      | -       | -           | -     |
| TDT          | -      | -       | -           | -     |
| Ki-67        | +      | +       | +           | +     |

“+” indicates positive, the number indicates positive degree; “-” indicates negative; blank indicates that the examination was not performed.

OUTCOME AND FOLLOW-UP

The patient’s international prognostic index was 5, which meant that she was in the high-risk group with a low 5-year survival rate[4]. Chidamide has a slower onset of action, and over the course of her treatment, her ascites did not improve. Unfortunately, after 41 d of chemotherapy, the patient died of multiple organ failure.
DISCUSSION

PTCL is an aggressive and rare disease that belongs to a heterogeneous group of mature T-cell lymphomas that constitute less than 15% of all non-Hodgkin lymphomas in adults\[5,6\]. The most common symptoms included lymphadenopathy and B symptoms (night sweats, fever, and weight loss). The initial findings in the patient were portal hypertension, ascites, splenomegaly, and routine biochemistry of ascites showing no infection. SAAG was 1.3, and HVPG was 10 mmHg. Ultrasound and CT showed hepatosplenomegaly and liver cirrhosis. CTA showed that there was no obstruction or
Figure 3 Liver computed tomographic arteriography. A: Spleen growth: spleen enhancement was less uniform, and patchy slightly hypointense areas were seen, not excluding infarcts or intrahepatic lymphatic stasis; B: The main portal vein and splenic vein were slightly thickened, the diameter of the main portal vein was approximately 1.5 cm, and there was no thrombus or collateral circulation opening; A and B: The vessel was smooth and unobstructed.

Figure 4 Pathology and immunochemistry were performed on four pieces of liver tissue. A: Histopathological examination by haematoxylin and eosin staining (100 ×); B: Histopathological examination by haematoxylin and eosin staining (400×) showed few hepatocytes that were watery and lipomatous and multiple small focal lymphoid cell infiltrates; C: Immunochemical staining shows CD3 positivity; D: Immunochemical staining shows CD7 positivity. H&E, haematoxylin and eosin.

To our knowledge, the gold standard for cirrhosis is liver biopsy, which can be performed for diagnostic compression of blood vessels before and after the trunk. Therefore, we excluded prehepatic and posthepatic portal hypertension and focused on intrahepatic portal hypertension[7], and the patient’s intrahepatic lymphatic stasis confirmed this speculation[8]. Although all examinations of our patients showed cirrhosis, the patient’s liver was enlarged, so we had to doubt the accuracy of the examination.
purposes when the diagnosis is uncertain. Before they are properly diagnosed, most patients are misdiagnosed as having hepatic cirrhosis, potentially delaying treatment. Consequently, the patient was subjected to a liver biopsy which confirmed the absence of cirrhosis; thus, this presentation was either PTCL or NOS (Figure 6).

Portal hypertension is a rare manifestation in lymphomas. By searching cases of PTCL-related portal hypertension and ascites (Table 3), we found that only one report[9] described a T-cell lymphoma patient presenting with portal hypertension and oesophageal and gastric varices but no ascites and whose diagnosis was confirmed by splenectomy. Four cases[10-13] mentioned ascites, but none reported whether there was portal hypertension and only reported diagnosis by ascites flow cytometry. The mechanism of portal hypertension is not mentioned in the above cases. We speculate that the reason for the noncirrhotic portal hypertension in this patient was intrahepatic lymph stasis. At the same time, visceral hyperdynamic circulation is one of the causes of increased portal blood flow and thus increased portal venous system pressure[14-16]. This case may be due to increased liver blood flow caused by tumours resulting in visceral hyperdynamic circulation leading to liver enlargement and portal hypertension. These two mechanisms together led to the development of noncirrhotic portal hypertension in this patient.

In the relevant literature, most patients are diagnosed based on ascites flow patterns, but in this case, due to insufficient sampling, the ascites flow pattern could not be successfully made. TIPS was used to perform portal pressure measurement and liver biopsy in this patient, and the diagnosis was finally made based on the biopsy results. TIPS is an interventional radiotherapy technique developed in the past 20 years. It uses the internal jugular vein as the puncture entrance, inserts the catheter through the superior vena cava, right atrium, and inferior vena cava, and inserts the hepatic vein into the hepatic vein under the guidance of an X-ray. Establishing an artificial shunt channel between them can not only measure the portal venous pressure to achieve the purpose of diagnosis but also reduce portal hypertension and achieve the purpose of treatment[17-19]. TIPS has been widely used for the diagnosis and treatment of portal hypertension[20]. TIPS is considered to be a successful and efficacious procedure with a 90% success rate[21,22]. Although there are unavoidable risks, recent studies have shown a high efficacy of TIPS compared to other treatments and presented an acceptable complication rate[23,24]. Research has shown that TIPS placement can be used for noncirrhotic portal hypertension[25]. At the same time, TIPS can also be used for liver biopsy to obtain a pathological diagnosis. When the patient was diagnosed with portal hypertension by TIPS, a liver biopsy was also performed, which
Table 3 A summary of demographic, radiographic, and clinical information from a review of five previously published cases of T-cell lymphomas with ascites and/or portal hypertension manifestations

| Ref. | Age, Gender | Course of disease | Clinical Symptoms | Supplementary Examination | Biopsy Source | Immunohistochemistry | Diagnosis | Invasion of other parts | Treatment | Prognosis |
|------|-------------|-------------------|-------------------|---------------------------|---------------|----------------------|-----------|------------------------|-----------|-----------|
| Ameri[13] | 61, F      | 2’W               | Abdominal discomfort | Ascites, hepatosplenomegaly | Ascites      | CD4(+), CD5(+), CD3(+), CD7(-), CD16(-), CD56(-), TdT(-) | PTCL, NOS   | Bone marrow            | No treatment       | NA        |
| Yamamoto[10] | 72, W      | 3’W               | Abdominal discomfort | Hydrothorax and ascites | Ascites      | CD2(+), CD3(+), CD45(+), CD4(-), CD8(-) | PTCL       | Thorax and abdomen     | Cyclophosphamide, mitoxantrone, vincristine, etoposide, bleomycin, and prednisolone | Died of multiple organ failure |
| Izban[12]  | 76, F      |                   | Abdominal tenderness | Ascites, splenomegaly     | Ascites      | CD2(+), CD3(+), CD5(+), CD7(+), CD45(+), CD4(-), CD8(-) | PTCL       | Bone marrow, liver     | CHOP chemotherapy   | Recurrence after chemotherapy |
| VakarLopez[11] | 49, W      | 3’M               | Abdominal tenderness | Ascites                   | Ascites      | CD3(+)                | PTCL, NOS   | No treatment            | Splenectomy         | NA        |
| Linder[9]  | 65, F      | 2’Y               | Pectoralgia, esophageal and gastric variceal bleeding (EGVB) | Splenomegaly, EGVB | spleen       | NA                   | Diffuse mixed-type T-cell lymphoma | Splenectomy | Bone marrow infiltration occurred 1 + year after the operation |

PTCL: Peripheral T-cell lymphoma; NOS: Not otherwise specified.

was the key to the final diagnosis of the patient. Therefore, when noncirrhotic portal hypertension is the main manifestation, all examinations suggest liver cirrhosis, but imaging does not conform to the characteristics of liver cirrhosis, such as liver enlargement. TIPS examination can be considered, which can not only measure portal pressure but also perform a biopsy to achieve the purpose of diagnosis, and the examination risk is relatively low. This study is helpful to reduce the missed diagnosis rate of lymphoma. PTCL-NOS has a poor prognosis, and the commonly used CHOP regimen is not effective[26-29]. Chidamide also takes at least 4 weeks to take effect. Early diagnosis can lead to more treatment opportunities and increase the prognosis of patients.

CONCLUSION

In conclusion, we describe a PTCL case presenting with ascites and noncirrhotic portal hypertension. Cases of noncirrhotic portal hypertension in PTCL are rare. When the clinical signs and auxiliary examinations suggest liver cirrhosis, as long as there is no concomitant with liver cirrhosis (hepatosplenomegaly), we should be alert to the possibility of other causes, such as lymphoma, reducing missed diagnosis of lymphoma.
Figure 6 Diagnosis flow charts. PTCL: Peripheral T-cell lymphoma; CT: Computed tomography; CTA: Computed tomography angiography; SAAG: Serum-ascites albumin gradient; PET-CT: Positron emission tomography-CT.

**FOOTNOTES**

**Author contributions:** Liao XY designed and performed the research; Wu MM analysed the data and wrote the paper; Wu J, Niu T, and Fu WJ cared for the patient, designed and analysed the research, and helped with writing the paper; Zhu LL, and Yang R participated in revising the manuscript; Lu Q carried out the ultrasound; Yao J performed imaging studies; all authors have read and approved the final manuscript.

**Informed consent statement:** Informed written consent was obtained from the patient for publication of this report and any accompanying images.

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest to disclose.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist. (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Country/Territory of origin:** China

**ORCID number:** Miao-Miao WU 0000-0003-3035-9914; Lin-Lin Zhu 0000-0002-4740-2838; Ting Niu 0000-0003-1580-1014; Jin Yao 0000-0002-4464-7143; Qiang Lu 0000-0002-4057-1997; Xiao-Yang Liao 000000034409674.

**S-Editor:** Ma YJ

**L-Editor:** A

**P-Editor:** Ma YJ
REFERENCES

1 Oluwasanjo A, Kartan S, Johnson W, Alpdogan O, Gru A, Mishra A, Haverkos BM, Gong J, Porcup P. Peripheral T-Cell Lymphoma, not Otherwise Specified (PTCL-NOS). Cancer Treat Res 2019; 176: 83-98 [PMID: 30596214 DOI: 10.1007/978-3-319-99716-2_4]

2 Das DK. Serous effusions in malignant lymphomas: a review. Diagn Cytopathol 2006; 34: 335-347 [PMID: 16604559 DOI: 10.1002/dc.20432]

3 Attanoos R. Lymphoproliferative conditions of the serosa. Arch Pathol Lab Med 2012; 136: 268-276 [PMID: 22372903 DOI: 10.5859/apmr.2011-0550-SA]

4 Sonnen R, Schmidt WP, Müller-Hermelink HK, Schmitz N. The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol 2005; 129: 366-372 [PMID: 15842660 DOI: 10.1111/j.1365-2141.2005.05478.x]

5 Vega F. Pathology and Pathogenesis of T-Cell Lymphoma. Clin Lymphoma Myeloma Leuk 2020; 20 Suppl 1: S89-S93 [PMID: 32862884 DOI: 10.1016/S2152-2650(20)30474-2]

6 Vega F, Amador C, Chadburn A, Feldman AL, Hsi ED, Wang W, Medeiros LJ. American Registry of Pathology Expert Opinions: Recommendations for the diagnostic workup of mature T cell neoplasms. Ann Diagn Pathol 2020; 49: 151623 [PMID: 32947231 DOI: 10.1016/j.anndiagpath.2020.151623]

7 Carrier P, Jacques J, Debette-Gratien M, Legros R, Sarabi M, Vidal E, Sautureau D, Bezanahary H, Ly KH, Loustaud-Ratti V. [Non-cirrhotic ascites: pathophysiology, diagnosis and etiology]. Rev Med Interne 2014; 35: 365-371 [PMID: 24406314 DOI: 10.1016/j.revmed.2013.12.001]

8 Rajesh S, Mukund A, Sureka B, Bansal K, Ronot M, Arora A. Non-cirrhotic portal hypertension: an imaging review. Abdom Radiol (NY) 2018; 43: 1991-2010 [PMID: 29564495 DOI: 10.1007/s00261-018-1570-8]

9 Lindor K, Rakeja J, Perrault J, Van Heerdon J. Noncirrhotic portal hypertension due to lymphoma. Reversal following splenectomy. Dig Dis Sci 1987; 32: 1056-1058 [PMID: 3497789 DOI: 10.1007/BF01297199]

10 Yamamoto Y, Kitajima H, Sakihana H, Shigek1 T, Fukuhara S. CD3+CD4-CD8-TCR-alpha+ T-cell lymphoma with clinical features of primary effusion lymphoma: an autopsy case. Int J Hematol 2001; 74: 422-446 [PMID: 11794701 DOI: 10.1016/S0021-2837(01)01371-6]

11 Vukan-López F, Yang M. Peripheral T-cell lymphoma presenting as ascites: a case report and review of the literature. Diagn Cytopathol 1999; 20: 382-384 [PMID: 10352913 DOI: 10.1002/(sici)1097-0339(19990620<6;382>a:aid-dc11>3.0.co;2-i)]

12 Izbani KF, Pooley RBJ Jr, Selvaggi SM, Alkan S. Cytologic diagnosis of peripheral T-cell lymphoma manifesting as ascites. A case report. Acta Cytol 2001; 45: 385-392 [PMID: 11393071 DOI: 11.1016/S0001-5434(01)93795-X]

13 Ameri MD, Parekh TM, Qian YW, Elghetany MT, Schnadig V, Nawgiri R. A case of peripheral T-cell lymphoma, not otherwise specified in a HCV and HTLV-II-positive patient, diagnosed by abdominal fluid cytology. J Gastrointest Oncol 2016; 7: S96-S99 [PMID: 27034820 DOI: 10.3978/j.issn.2078-6891.2015.0554]

14 Vuppulanchi R, Mathur K, Pyko M, Samala N, Chalasani N. Liver Stiffness Measurements in Patients with Noncirrhotic Portal Hypertension–The Devil Is in the Details. Hepatology 2018; 68: 2383-2440 [PMID: 30014586 DOI: 10.1002/hep.30167]

15 Khanna R, Sarin SK. Noncirrhotic Portal Hypertension: Current and Emerging Perspectives. Clin Liver Dis 2019; 23: 781-807 [PMID: 31563222 DOI: 10.1016/j.clld.2019.07.006]

16 Da BI, Koh C, Heller T. Noncirrhotic portal hypertension. Curr Opin Gastroenterol 2018; 34: 140-145 [PMID: 29465431 DOI: 10.1097/MOG.0000000000000433]

17 Bucics T, Lampichker K, Vierziger C, Schoder M, Wolf F, Bauer D, Simbrunner B, Hartl L, Jacobs M, Scheiner B, Trauner M, Gruenberger T, Karnel F, Mandorfer M, Reiberger T. Covered Transjugular Intrahepatic Portosystemic Shunt Improves Hypersplenism-Associated Cytopenia in Cirrhosis. Dig Dis Sci 2022 [PMID: 35261618 DOI: 10.1007/s00298-022-07441-6]

18 Artru F, Moschouri E, Denys A. Direct intrahepatic portocaval shunt (DIPS) or transjugular transcalve intrahepatic portosystemic shunt (TIPS) to treat complications of portal hypertension: Indications, technique, and outcomes beyond Budd-Chiari syndrome. Clin Res Hepatol Gastroenterol 2022; 46: 101858 [PMID: 34999250 DOI: 10.1016/j.clinre.2022.118495]

19 Madhusudhan KS, Sharma S, Srivastava DN. Percutaneous radiological interventions of the portal vein: a comprehensive review. Acta Radiol 2022; 2841851221080554 [PMID: 35187977 DOI: 10.1177/02841851221080554]

20 Wang C, Liu J, Yao J, Ju S, Wang Y, Yang C, Bui Y, Yao W, Li T, Chen Y, Huang S, Xiong B. Transjugular intrahepatic portosystemic shunt in patients with autoimmune hepatitis-induced cirrhosis and variceal bleeding. Abdom Radiol (NY) 2022; 47: 1464-1472 [PMID: 35230498 DOI: 10.1007/s00261-022-03465-w]

21 Tandon B, Ramachandran J, Narayana S, Muller K, Pathi R, Wigg AJ. Outcomes of transjugular intrahepatic portosystemic shunt procedures: a 10-year experience. J Med Imaging Radiat Oncol 2021; 65: 665-662 [PMID: 33687155 DOI: 10.1111/1755-4985.13168]

22 Greval S, Sidhu R, Elhassan M. Rings Flying Around: A rare complication of Transjugular Intrahepatic Portosystemic Shunt. Respir Med Case Rep 2022; 36: 101586 [PMID: 35242514 DOI: 10.1016/j.rmcr.2022.101586]

23 Lee HJ, Lee SW. The role of transjugular intrahepatic portosystemic shunt in patients with portal hypertension: Advantages and pitfalls. Clin Mol Hepatol 2022; 28: 121-134 [PMID: 34571587 DOI: 10.3350/clinmolhepatol.2021.0239]

24 Quin Z, Zhu W, Yan H, Wang G, Zuo M, Qi H, Jiang W, Xue J, Zhang F, Gao F. Single-Centre Retrospective Study Using Propensity Score Matching Comparing Left Versus Right Internal Jugular Vein Access for Transjugular Intrahepatic Portosystemic Shunt (TIPS) Creation. Cardiovasc Intervent Radiol 2022; 45: 563-569 [PMID: 34973068 DOI: 10.1007/s00270-021-03023-9]

25 Shreve LA, O’Leary C, Clark TWI, Stavropoulos SW, Soulken MC. Transjugular intrahepatic portosystemic shunt for the management of symptomatic malignant pseudocirrhosis. J Gastrointest Oncol 2022; 13: 279-287 [PMID: 35284108 DOI: 10.21037/jgo-21-501]
26 Liu W, Ji X, Song Y, Wang X, Zheng W, Lin N, Tu M, Xie Y, Ping L, Ying Z, Zhang C, Deng L, Wu M, Feng F, Leng X, Sun Y, Du T, Zhu J. Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades. *Cancer Med* 2020; 9: 3765-3774 [PMID: 32281275 DOI: 10.1002/cam4.3037]

27 Iżykowska K, Rassek K, Korsak D, Przybylski GK. Novel targeted therapies of T cell lymphomas. *J Hematol Oncol* 2020; 13: 176 [PMID: 33384022 DOI: 10.1186/s13045-020-01006-w]

28 Foster C, Kuruvilla J. Treatment approaches in relapsed or refractory peripheral T-cell lymphomas. *F1000Res* 2020; 9 [PMID: 32934797 DOI: 10.12688/f1000research.22257.1]

29 Allen PB, Pro B. Therapy of Peripheral T Cell Lymphoma: Focus on Nodal Subtypes. *Curr Oncol Rep* 2020; 22: 44 [PMID: 32297075 DOI: 10.1007/s11912-020-00902-1]
